Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

NCT05823480 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Withdrawn -ctms

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation
DRUG: Azacitidine
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspirate
PROCEDURE: Bone Marrow Biopsy
PROCEDURE: Echocardiography
BIOLOGICAL: Magrolimab
PROCEDURE: Multigated Acquisition Scan
OTHER: Questionnaire Administration

Sponsor

City of Hope Medical Center

Collaborators

[object Object]